Guardant Health, Inc. and ConcertAI announced a collaboration agreement to provide biopharmaceutical companies with access to the first multi-modal real-world data (RWD) that integrates comprehensive patient electronic medical record (EMR) data with genomic and epigenomic tumor profiling information.
This joint RWD solution aims to provide critical clinical context to an extensive database of solid tumor cancer patients with multiple liquid biopsies. This will allow biopharma collaborators to better interpret disease biology, identify drivers of tumor evolution, and understand resistance mechanisms.
Helmy Eltoukhy, Guardant Health co-CEO, stated that this partnership provides evidence and outcomes researchers with robust data and AI-based modeling for unprecedented insight into a patient’s cancer journey. The integrated data will include methylation data from biomarker tests run on the Guardant Infinity smart liquid biopsy platform, offering new dimensions of research insights.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.